| Autor: |
Gupta, S, Dovey, OM, Domingues, AF, Cyran, OW, Cash, CM, Giotopoulos, G, Rak, J, Cooper, J, Gozdecka, M, Asby, RJ, Al-Jabery, N, Hernandez, V, Prabakaran, S, Huntly, BJ, Vassiliou, GS, Pina, C |
| Jazyk: |
angličtina |
| Rok vydání: |
2021 |
| Popis: |
Competing Interest Statement: VH-H is co-Founder and CSO of Axovia Therapeutics. SP is the CEO of NonExomics, Inc. Axovia and NonExomics did not provide funding to this study, and did not influence study design, execution, data analysis or interpretation. bioRxiv posts many COVID19-related papers. A reminder: they have not been formally peer-reviewed and should not guide health-related behavior or be reported in the press as conclusive. Copyright 2021 The Authors. Transcriptional variability facilitates stochastic cell diversification and can in turn underpin adaptation to stress or injury. We hypothesize that it may analogously facilitate progression of pre-malignancy to cancer. To investigate this, we initiated pre-leukemia in mouse cells with enhanced transcriptional variability due to conditional disruption of the histone lysine acetyltransferase gene Kat2a. By combining single-cell RNA-sequencing of pre-leukemia with functional analysis of transformation, we show that Kat2a loss results in global variegation of cell identity and accumulation of pre-leukemic cells. Leukemia progression is subsequently facilitated by destabilization of ribosome biogenesis and protein synthesis, which confer a transient transformation advantage. The contribution of transcriptional variability to early cancer evolution reflects a generic role in promoting cell fate transitions, which, in the case of well-adapted malignancies, contrastingly differentiates and depletes cancer stem cells. In other words, transcriptional variability confers forward momentum to cell fate systems, with differential multi-stage impact throughout cancer evolution. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
